Top

Tag: ANCA


FDA, Regulations

FDA Approves ChemoCentryx’s Tavenos

October 8, 2021

Via: Biopharm International

ChemoCentryx, a biopharmaceutical company targeting the chemokine and chemoattractant systems, announced that FDA approved Tavenos (avacopan), an orally-administered selective complement 5a receptor inhibitor, on Oct. 8th, 2021. Avacopan was approved as an adjunctive treatment for adults with severe active anti-neutrophil […]